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Introduction
About 170,000 patients each year undergo
pacemaker implantation in the United States,1
and pacemaker renewal is increasingly common
with the aging population.2 Fibrosis around the
pacemaker leads in the cardiac chambers, supe-
rior vena cava (SVC), or subclavian and innomi-
nate veins, can make lead removal and replace-
ment difficult. Telescoping sheaths made of
polymer and/or steel material can be applied with
countering force for fibrous overgrowth that re-
sists traction.3–5 However, when these are compli-
cated with SVC syndrome, surgical removal and
reimplantation of pacing leads, together with ve-
nous reconstruction has been the standard treat-
ment.6,7 This article reports the authors’ initial ex-
perience with a percutaneous approach that
consists of extraction of the pacemaker system
with an excimer laser sheath, followed by percu-
taneous venous revascularization and stent place-
ment, and implantation of a new pacemaker gen-
erator and leads with the same venous access.
Percutaneous Techniques
Excimer Laser Sheath Pacemaker Lead
Extraction
The technique and the procedural outcome
for the pacemaker lead extraction with the laser
sheath have been previously described.8 Briefly,
the 35-cm long sheath consists of thin inner (8.4
Fr) and outer (12 Fr) polymer walls between
which a single layer of optical fibers has been spi-
rally wrapped and ends as a single circumferential
ring at the distal tip. The proximal end of the
sheath is attached to the CVX-300 Excimer XeCl
Laser System (Spectranetics Corp., Colorado
Springs, CO, USA). This system has an energy de-
livery of 30–60 mJ/mm2 in 135-ns pulses and a fre-
quency of 25–40 Hz. The combined effect of pho-
tochemolysis and photothermal ablation causes
the tissue in contact with the distal tip to disinte-
grate into particles , 5 mm in diameter. Since the
penetration depth of the system is approximately
100 mm, the laser energy is completely absorbed
by the tissue, allowing local and precise removal
of the fibrotic tissue directly surrounding the
leads.
After the locking stylet is placed in the lead, a
Teflon outer sheath is preloaded over the laser
sheath before the stylet and leads are threaded
through the assembly. When the assembly reaches
the first adhesion, a 5-second burst of excimer
laser energy is delivered during gentle forward
pressure on the laser sheath and withdrawal trac-
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Figure 1. (Patient 1): (A and B) The serial
angiograms demonstrated the retrieval of the
atrial pacemaker leads (short solid arrow) and
the ventricular lead (short open arrow) using
the excimer laser sheath (long arrow). (C–E)
The venogram confirmed severe stenosis in
the right brachiocephalic vein and superior
vena cava (arrowhead), which were
successfully recanalized with balloon and
stent.
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tion on the locking stylet. Continuous advance-
ment of the assembly is performed until the lead is
free from adhesions or until the sheath tip is a few
millimeters away from the endocardium. At the
end, the outer sheath is advanced, and counter-
traction is applied to remove the lead.
Intravenous Stenting
Following lead extraction, a cinevenogram is
recorded by injecting contrast antegradely through
the previously placed 12 Fr sheath placed ipsilat-
erally in the subclavian vein, and an 18-gauge an-
giocath in the contralateral antecubital fossa. To
further define the anatomy, additional venograms
can be recorded by injecting contrast via a multi-
purpose catheter placed distal to the obstruction
via an 11 Fr sheath in the right or left femoral vein.
The lesion is crossed with an 0.035-inch guidewire
(e.g., Magic Torque or Glidewire, Boston Scien-
tific, Watertown, MA, USA). Following balloon
catheter dilatation, self-expanding nitinol stent(s)
are deployed. Postdilation with noncompliant bal-
loon catheter is performed to optimize angio-
graphic results. The new pacemaker leads are then
implanted through the stented vein. Postprocedu-
ral antiplatelet therapy consists of clopidogrel for
1–3 months, in addition to life-long aspirin.
Case Reports
Patient 1
A 24-year-old woman was referred for re-
placement of the pacemaker system 11 years after
implantation because of insulation failure of the
pacemaker leads and SVC syndrome secondary to
partial thrombosis within the right subclavian
vein. The atrial and ventricular pacemaker leads
were extracted without difficulty using excimer
laser sheaths (Fig. 1, Table I). Sequential balloon
inflations (8 3 30 and 10 3 20 mm Opta LP,
Cordis, Miami, FL, USA) across the occlusive site
resulted in significant recoil and a small dissec-
tion. A 10 3 20 mm self-expanding SMART
(Cordis) stent was deployed in the right brachio-
cephalic vein, followed by implantation of new
dual chamber pacemaker system over the right
pectoral region. She was discharged on the fol-
lowing day with 3 months of clopidogrel and life-
long aspirin.
Patient 2
At 16 years after pacemaker implantation,
the 48-year-old patient presented with SVC syn-
drome. After laser-assisted extraction, venogram
confirmed severe stenosis in the left innominate






Patient Implant Lesion Site Stenosis Guidewire Catheter(s) Stent Type Final Results
1 11 R-BcV, SVC 95/0 Magic Torque 8 3 30 and 10 3 20 10 3 20 mm SMART Successful
mm Opta LP
2 16 SVC, L-BcV 90/0 Magic Torque 7 3 40 and 12 3 40 BcV: 14 3 60 SMART Successful
mm Opta LP SVC: 14 3 40 SMART
3 6 R-SubV, SVC 90/0 Glidewire 8 3 40 Opta LP, R-SubV: 12 3 40 mm Successful
12 3 40 Medi-Tech SMART
SVC: 14 3 20 SMART
4 17 SVC, R-BcV, 100/0 Glidewire SVC: 10 3 40 mm R-SubV: 10 3 40 mm Ruptured valve
R-SubV R-InV: 12 3 40 mm SMART, 10 3 20 chordae




BcV 5 brachiocephalic vein; R 5 right; SubV 5 subclavian vein; SVC 5 superior vena cava; L 5 left.
Figure 2. (Patient 2): (A and C) Extraction of the old
pacemaker leads within the left brachiocephalic vein
using excimer laser sheath (long arrow). (Atrial lead,
short solid arrow; ventricular lead, short open arrow)
(D–F) The location of the occlusive site was confirmed
within the left brachiocephalic vein (arrow head).
Balloon predilation was carried out, followed by stenting
within the left brachiocephalic vein and the superior
vena cava.
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lesions were crossed with a Magic Torque wire
(Table I). Balloon predilation of the brachio-
cephalic vein and SVC was performed using 7 3
40 mm Opta LP catheter, and this was followed
by stent placement in each of the brachiocephalic
veins (14 3 60 mm SMART stent) and SVC (14 3
40 mm SMART stent). Postdilation was per-
formed with the use of 12 3 40 mm Opta LP
catheter. A new pacemaker system was im-
planted at the same site and the patient was dis-
charged on the following day after an uneventful
recovery.
Patient 3
A 45-year-old woman had a pacemaker im-
plantation 6 years ago. Three months prior to in-
dex hospitalization, she developed right brachio-
cephalic vein thrombosis and underwent
thrombolysis and balloon angioplasty. She pre-
sented with recurrence of symptoms.
After laser-assisted lead extraction, a
venogram through an 8 Fr Mullins sheath (USCI,
Billerica, MA, USA) inserted in the right antecu-
bital vein confirmed a complete occlusion of the
right brachiocephalic vein and severe stenosis in
SVC. After crossing the lesions with a 0.035-inch
Glidewire and balloon dilation using 8 3 40 mm
Opta LP balloon catheter, a 12 3 40 mm SMART
stent was deployed across the occluded portion of
the right subclavian vein and was postdilated with
a 12 3 40 mm Medi-Tech (Boston Scientific, Wa-
tertown, MA, USA) balloon catheter. With the
pullback of the Mullins sheath from the right
atrium to the right brachiocephalic vein, a 6-
mmHg gradient was detected and hence a 14 3 20
mm SMART stent was deployed in the SVC. No
residual stenosis was present and a new pace-
maker system was implanted through the same
vessels. The patient was discharged the next day
on aspirin and clopidogrel.
Patient 4
A 49-year-old man presented with recurrent
SVC syndrome, which manifested as facial and
upper extremity edema, exertional dyspnea, and
presyncope, at 17 years after his first permanent
pacemaker implantation. He had history of bilat-
eral brachiocephalic venous occlusion, and pace-
maker pocket infection that required surgical de-
bridement. After an apparently uneventful lead
extraction with laser assistance, a venogram re-
vealed a subtotal occlusion of the right subclavian
vein. The lesion was crossed with a stiff angled
Glidewire. Balloon inflation was performed
within the innominate and the subclavian veins,
and the SVC, using a 10 3 40 and a 12 3 40 mm
Opta LP balloon. A 10 3 40 and a 10 3 20 mm
SMART stents were deployed within the subcla-
vian veins due to residual stenosis. The venous
pressure dropped from 40 to 14 mmHg with the
procedure. At this time, severe tricuspid regurgi-
tation was noted secondary to a torn chordae of
the anterior tricuspid valve leaflet, prohibiting
transvenous placement of the permanent pace-
maker lead in the right ventricle. The patient un-
derwent surgical replacement of the tricuspid
valve and epicardial electrode implantation.
Follow-Up
During a median of 9 (range 6–12) months of
follow-up, no patients had return of symptoms of
venous obstruction or pacemaker malfunction.
Discussion
This article describes a percutaneous ap-
proach for the treatment of SVC syndrome caused
by fibrotic adhesions around permanent pace-
maker leads. With an increasing number of pa-
tients receiving pacemakers and implantable car-
dioverter defibrillators, secondary venous
obstruction is likely to become more common.
Through the joint effort of electrophysiologists
and interventional cardiologists, this originally
complex problem can be resolved by a “one-step”
percutaneous approach. This method is associ-
ated with considerable less discomfort to the pa-
tients, and can be considered as an alternative to
surgery.
The efficacy of lead extraction using an ex-
cimer laser has been studied in the Pacing Lead
Extraction with the Excimer Sheath (PLEXES)
trial.8,9 The success rate of lead extraction was
95%. Of 153 patients randomized to laser-assisted
extraction, 4 (2.4%) patients had immediate major
complications. These included laceration of the
lateral atrial wall in two patients resulting in tam-
ponade and one death, and laceration of SVC
causing hemothorax. One patient had severe tri-
cuspid insufficiency after failed lead extraction
and was subsequently treated medically. Al-
though these complications were at times life-
threatening, the incidence remained low and was
comparable to historical controls using the tradi-
tional approach.10 Laser energy reduced the coun-
terpressure required to extract the leads, and was
not considered related to any of the major compli-
cations. In light of the potential periprocedural
complications, surgical backup for percutaneous
lead extraction is mandatory.
Direct comparison of the efficacy between an-
gioplasty alone and stenting of venous lesions has
not been reported. Several series have suggested
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that stenting provides satisfactory early and inter-
mediate results.11–15 However, most of the previ-
ous series involved cases related to indwelling
dialysis catheters or to extrinsic compression due
to malignancy. Since many of these series in-
volved patients with limited life expectancy, the
exact long-term patency rate remains unknown.
Initial procedural success rates varied from 85 to
100% and all successful cases resulted in symp-
tomatic relief of central venous obstruction. In the
series by Oderich et al.15 94% of the patients were
event-free at 1 year.
Unlike the present cases, stainless steel self-
expanding stents were used in previous series of
central venous stenting.12,13 Compared with stain-
less steel self-expanding stents, nitinol stents have
greater radial strength, conform better in tortuous
vessels, and may have lower restenosis rates. The
use of adjunctive thrombolysis and thromboaspi-
ration techniques has been used by some investi-
gators.11 Antithrombin or fibrinolytic agents are
not routinely used to prevent bleeding complica-
tions secondary to occult venous laceration or per-
foration during pacemaker lead removal. Consen-
sus for antiplatelet therapy after central venous
stenting has not been established. Currently, the
authors routinely administer clopidogrel for 3
months in addition to lifelong aspirin.
Summary
The preliminary data suggest that percuta-
neous laser-assisted lead extraction followed by
intravenous stenting and reimplantation of per-
manent pacemaker is feasible, safe, and may pro-
vide an alternative to surgery for a complex prob-
lem. The true long-term benefit of this approach
will require observation of a larger number of pa-
tients for several years after the procedure.
